Search

Your search keyword '"Davis, I. D."' showing total 177 results
Start Over Author "Davis, I. D."
177 results on '"Davis, I. D."'

5. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Author

Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., Eeles, R. A., Fanti, S., Gleave, M. E., Heidenreich, A., Hussain, M., James, N. D., Lecouvet, F. E., Logothetis, C. J., Mastris, K., Nilsson, S., Oh, W. K., Olmos, D., Padhani, A. R., Parker, C., Rubin, M. A., Schalken, J. A., Scher, H. I., Sella, A., Shore, N. D., Small, E. J., Sternberg, C. N., Suzuki, H., Sweeney, C. J., Tannock, I. F., and Tombal, B.

Published
2015
Full Text
View/download PDF

13. Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Author

Bamias, A. De Santis, M. Arranz, J. A. Grande, E. and Galsky, M. D. Kikuchi, E. Park, S. H. De Giorgi, U. and Garcia del Muro, X. Mencinger, M. Alekseev, B. Puente, J. and Izumi, K. Gumus, M. Mellado Gonzalez, B. Li, J-R. and Quach, C. Ding, B. Bernhard, S. Davis, I. D.

Published
2020

27. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Author

Davis, I. D., Martin, A. J., Stockier, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G., McCaffrey, J., McDermott, R., Mcjannett, M., North, S. A., Parnis, F., Parulekar, W., and Pook, D. W.

Subjects
*CASTRATION-resistant prostate cancer, *PROSTATE cancer, *METASTASIS, *PROSTATE-specific antigen, *PROGRESSION-free survival
Abstract

BACKGROUND Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer. METHODS In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point was overall survival. Secondary end points included progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free survival, and adverse events. RESULTS A total of 1125 men underwent randomization; the median follow-up was 34 months. There were 102 deaths in the enzalutamide group and 143 deaths in the standardcare group (hazard ratio, 0.67; 95% confidence interval [Cl], 0.52 to 0.86; P=0.002). Kaplan-Meier estimates of overall survival at 3 years were 80% (based on 94 events) in the enzalutamide group and 72% (based on 130 events) in the standard-care group. Better results with enzalutamide were also seen in PSA progression-free survival (174 and 333 events, respectively; hazard ratio, 0.39; PcO.001) and in clinical progressionfree survival (167 and 320 events, respectively; hazard ratio, 0.40; PcO.001). Treatment discontinuation due to adverse events was more frequent in the enzalutamide group than in the standard-care group (33 events and 14 events, respectively). Fatigue was more common in the enzalutamide group; seizures occurred in 7 patients in the enzalutamide group (1%) and in no patients in the standard-care group. CONCLUSIONS Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetaxel. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

28. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Author

Stukalin, I., Wells, J. C., Graham, J., Yuasa, T., Beuselinck, B., Kollmansberger, C., Ernst, D. S., Agarwal, N., Le, T., Donskov, F., Hansen, A. R., Bjarnason, G. A., Srinivas, S., Wood, L. A., Alva, A. S., Kanesvaran, R., Fu, S. Y. F., Davis, I. D., Choueiri, T. K., and Heng, D. Y. C.

Subjects
RENAL cell carcinoma, VASCULAR endothelial growth factor receptors
Abstract

Objectives In the present study, we explored the real-world efficacy of the immuno-oncology checkpoint inhibitor nivolumab and the tyrosine kinase inhibitor cabozantinib in the second-line setting. Methods Using the International Metastatic Renal Cell Carcinoma Database Consortium (imdc) dataset, a retrospective analysis of patients with metastatic renal cell carcinoma (mrcc) treated with nivolumab or cabozantinib in the second line after prior therapy targeted to the vascular endothelial growth factor receptor (vegfr) was performed. Baseline characteristics and imdc risk factors were collected. Overall survival (os) and time to treatment failure (ttf) were calculated using Kaplan-Meier curves. Overall response rates (orrs) were determined for each therapy. Multivariable Cox regression analysis was performed to determine survival differences between cabozantinib and nivolumab treatment. Results The analysis included 225 patients treated with nivolumab and 53 treated with cabozantinib. No significant difference in median os was observed: 22.10 months [95% confidence interval (ci): 17.18 months to not reached] with nivolumab and 23.70 months (95% ci: 15.52 months to not reached) with cabozantinib (p = 0.61). The ttf was also similar at 6.90 months (95% ci: 4.60 months to 9.20 months) with nivolumab and 7.39 months (95% ci: 5.52 months to 12.85 months) with cabozantinib (p = 0.20). The adjusted hazard ratio (hr) for nivolumab compared with cabozantinib was 1.30 (95% ci: 0.73 to 2.3), p = 0.38. When adjusted by imdc criteria and age, the hr was 1.32 (95% ci: 0.74 to 2.38), p = 0.35. Conclusions Real-world imdc data indicate comparable os and ttf for nivolumab and cabozantinib. Both agents are reasonable therapeutic options for patients progressing after initial first-line vegfr-targeted therapy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

30. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

Author

Xu, C-F, primary, Johnson, T, additional, Garcia-Donas, J, additional, Choueiri, T K, additional, Sternberg, C N, additional, Davis, I D, additional, Bing, N, additional, Deen, K C, additional, Xue, Z, additional, McCann, L, additional, Esteban, E, additional, Whittaker, J C, additional, Spraggs, C F, additional, Rodríguez-Antona, C, additional, Pandite, L N, additional, and Motzer, R J, additional

Published
2015
Full Text
View/download PDF

32. A pilot study of the safety, efficacy, and effects on functional imaging of the combination of cG250 and sunitinib in patients (pts) with advanced renal cell carcinoma (RCC).

Author

Ciprotti, M., primary, Davis, I. D., additional, Pook, D. W., additional, Lee, F. T., additional, Cavicchiolo, T., additional, Lee, S. T., additional, Chappell, B., additional, O'Keefe, G. J., additional, Tochon-Danguy, H., additional, Smyth, F. E., additional, Hopkins, W., additional, and Scott, A. M., additional

Published
2011
Full Text
View/download PDF

39. O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

Author

Watson, A J, primary, Middleton, M R, additional, McGown, G, additional, Thorncroft, M, additional, Ranson, M, additional, Hersey, P, additional, McArthur, G, additional, Davis, I D, additional, Thomson, D, additional, Beith, J, additional, Haydon, A, additional, Kefford, R, additional, Lorigan, P, additional, Mortimer, P, additional, Sabharwal, A, additional, Hayward, O, additional, and Margison, G P, additional

Published
2009
Full Text
View/download PDF

46. Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions

Author

Murphy, R., primary, Green, S., additional, Ritter, G., additional, Cohen, L., additional, Ryan, D., additional, Woods, W., additional, Rubira, M., additional, Cebon, J., additional, Davis, I. D., additional, Sjolander, A., additional, Kypridis, A., additional, Kalnins, H., additional, McNamara, M., additional, Moloney, M. B., additional, Ackland, J., additional, Cartwright, G., additional, Rood, J., additional, Dumsday, G., additional, Healey, K., additional, Maher, D., additional, Maraskovsky, E., additional, Chen, Y.‐T., additional, Hoffman, E. W., additional, Old, L. J., additional, and Scott, A. M., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results